Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab as Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT03322267Phase 2Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Oct 2018
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Taiwan University Hospital. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03322267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03322267.